Riskpilot← Back to searchSign inGet full accessColumella Innovation AB
ABActiveOrg 5591522254Hisingsgården MedelplanaResearch and experimental development on natural sciences and engineering · NACE 7210Est. 20180 employees
Revenue 2024
SEK 812K
+217% vs 2023
EBITDA margin
31.6%
+1468% vs 2023
Equity ratio
41.3%
Financial strength
Net profit 2024
SEK 154K
+1335% vs 2023
| Revenue | SEK 812K | +217% |
| EBITDA | SEK 256K | +1468% |
| Net profit | SEK 154K | +1335% |
| Total assets | SEK 855K | +139% |
| Equity | SEK 353K | +78% |
| Employees | 0 | — |
Legal name
Columella Innovation AB
Org number
5591522254
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
12 mars 2018
Share capital
SEK 50 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamöterna
Company purpose
Columella Innovation AB skall vara ett innovations- och produktutvecklingsföretag för ny innovativ bioteknik baserat på digitalisering och naturvetenskaplig forskning för produkter och tjänster för främst livsmedels- och bioenergiproduktion. Därutöver också värdepappershandel.
Address
Hisingsgården Medelplana
Email
jan.rundqvist@columella-innovation.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 249 | — | 47 | 257 | 812 |
| Staff expenses | — | — | −15 | −176 | −493 |
| EBITDA | 221 | 0 | −18 | 16 | 256 |
| Depreciation & amort. | −0 | — | — | — | — |
| EBIT | 221 | 0 | −18 | 16 | 256 |
| Net financials | −110 | — | −0 | −3 | 7 |
| Profit before tax | 165 | 0 | −18 | 13 | 196 |
| Tax | −35 | — | 1 | −2 | −42 |
| Net profit | 130 | — | −17 | 11 | 154 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 331 | — | 306 | 358 | 855 |
| Equity | 181 | — | 188 | 199 | 353 |
| Long-term debt | 0 | — | 50 | 50 | 50 |
| Short-term debt | 94 | — | 13 | 55 | 329 |
| Total debt | 94 | — | 63 | 105 | 379 |
EBITDA margin
31.6%
This company
15.8%
Market median
+100% vs market
20202024
Equity ratio
41.3%
This company
38.2%
Market median
+8% vs market
20202024
Return on equity
43.7%
This company
18.4%
Market median
+138% vs market
20202024
Net profit margin
19.0%
This company
8.1%
Market median
+135% vs market
20202024
Asset turnover
0.95×
This company
1.12×
Market median
+15% vs market
20202024
Debt / equity
1.42×
This company
0.62×
Market median
-129% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (4) | ||
| Board of Directors | 2022 | |
| Deputy Board Member | 2022 | |
| Chairman | 2022 | |
| Deputy Board Member | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Columella Innovation AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Anders Tord Åke Jonsson | Board of Directors | 0 companies |
| Lena Christina Rundqvist | Deputy Board Member | 0 companies |
| Jan Arvid Rundqvist | Chairman | 0 companies |
| Anna Cecilia Koch | Deputy Board Member | 0 companies |